We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Stellar’s Exclusive License Agreement on Bayer Innovations/Stellar KLH Technology
News

Stellar’s Exclusive License Agreement on Bayer Innovations/Stellar KLH Technology

Stellar’s Exclusive License Agreement on Bayer Innovations/Stellar KLH Technology
News

Stellar’s Exclusive License Agreement on Bayer Innovations/Stellar KLH Technology

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Stellar’s Exclusive License Agreement on Bayer Innovations/Stellar KLH Technology"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Stellar Biotechnologies, Inc. has announced that it has acquired an exclusive, irrevocable, worldwide, sub-licensable and royalty-free license to the technology developed through a Collaborative Research Agreement between Stellar and Bayer Innovations (BIG).

The license includes a carve-out by BIG for use of the technology in its non-Hodgkin lymphoma (NHL) vaccine which is currently under development. Otherwise, the license leaves Stellar free to commercialize the technology, exclusively, in all other fields.

Stellar CEO, Frank Oakes said, ”The technology developed through the collaboration with BIG represents a breakthrough in the production of highly characterized, immunogenically potent carrier proteins (ICPs), not only in terms of quality and purity, but also for cost management in the final drug product. The technology will be integrated into BIG’s NHL vaccine platform, and commercialized broadly by Stellar for other vaccines and related products.”
Advertisement